Eskisehir Osmangazi University
ogu.edu.trLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
147
Active
15
Phase 3
1
Total enrollment
27,521
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension | — | — | — | — | — | 1 | |
| ISB + paracetamol IV 3*1 | — | — | — | — | — | 1 | |
| ISB+ paracetamol IV 3*1 +deksketoprofen IV 2*1 | — | — | — | — | — | 1 |
Next readouts
- 2026-03-01
- 2027-01-01
Top conditions
- Postoperative Pain4
- Pleural Diseases4
- Anxiety4
- Pain, Postoperative4
- Obesity4
- Breastfeeding4
- Pain4
- Postoperative Complications3
Frequently asked questions about Eskisehir Osmangazi University
- How many clinical trials does Eskisehir Osmangazi University have on ClinicalTrials.gov?
- Eskisehir Osmangazi University is listed as the lead sponsor on 147 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Eskisehir Osmangazi University's trials are in Phase 3?
- 1 of Eskisehir Osmangazi University's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Eskisehir Osmangazi University focus on?
- Eskisehir Osmangazi University's most-studied conditions on ClinicalTrials.gov are Postoperative Pain, Pleural Diseases, Anxiety, Pain, Postoperative, Obesity.
- When are Eskisehir Osmangazi University's next clinical trial readouts?
- Eskisehir Osmangazi University has 2 upcoming primary-completion readouts tracked here; the soonest is “Effects of Saccharomyces Boulardii CNCM I-745 on Antibiotic-Associated Perturbation in Children Treated for Acute Respiratory Infections (RESTORE Study)”, expected around 2026-03-01.